SCH 351448
Latest Information Update: 06 Dec 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source; Schering-Plough
- Class Antihyperlipidaemics
- Mechanism of Action LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 03 Nov 2000 Preclinical development for Hyperlipidaemia in USA (Unknown route)